RSL Electronics Ltd. (TLV:RSEL)

Achilles Therapeutics Income Statement

Financials in millions ILS. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	54.04	31.12	35.86	23.84	20.71
Revenue Growth (YoY)	73.69%	-13.23%	50.41%	15.12%	-6.07%
Cost of Revenue	25.1	16.27	20.07	15.49	13.38
Gross Profit	28.94	14.84	15.79	8.36	7.34
Selling, General & Admin	8.57	7.6	7.5	6.76	6.75
Research & Development	3.63	1.03	0.76	0.69	2.17
Other Operating Expenses	-	-0.18	0.07	0.01	-0.27
Operating Expenses	12.19	8.44	8.33	7.46	8.65
Operating Income	16.75	6.4	7.46	0.9	-1.31
Interest Expense	-0.33	-0.3	-0.27	-0.35	-0.23
Interest & Investment Income	0.58	0.39	0.03	0	0.05
Currency Exchange Gain (Loss)	0.64	-	0.78	-0.18	-0.2
EBT Excluding Unusual Items	17.64	6.49	8	0.38	-1.69
Other Unusual Items	-0.08	-	-	-	-
Pretax Income	17.56	6.49	8	0.38	-1.69
Income Tax Expense	1.38	0.55	0.56	0.11	0.16
Net Income	16.18	5.94	7.44	0.27	-1.85
Net Income to Common	16.18	5.94	7.44	0.27	-1.85
Net Income Growth	172.50%	-20.18%	2676.12%	-	-
Shares Outstanding (Basic)	10	10	10	10	10
Shares Outstanding (Diluted)	10	10	10	10	10
EPS (Basic)	1.60	0.59	0.74	0.03	-0.18
EPS (Diluted)	1.60	0.59	0.74	0.03	-0.18
EPS Growth	172.50%	-20.18%	2676.22%	-	-
Free Cash Flow	-5.5	9.9	13.9	-6.53	0.26
Free Cash Flow Per Share	-0.54	0.98	1.37	-0.65	0.03
Dividend Per Share	1.857	0.246	0.380	-	-
Dividend Growth	654.85%	-35.26%	-	-	-
Gross Margin	53.56%	47.71%	44.02%	35.05%	35.42%
Operating Margin	31.00%	20.58%	20.80%	3.78%	-6.34%
Profit Margin	29.95%	19.09%	20.75%	1.12%	-8.92%
Free Cash Flow Margin	-10.18%	31.80%	38.77%	-27.40%	1.27%
EBITDA	16.97	6.5	8.43	1.96	-0.19
EBITDA Margin	31.40%	20.90%	23.52%	8.23%	-0.90%
D&A For EBITDA	0.22	0.1	0.97	1.06	1.13
EBIT	16.75	6.4	7.46	0.9	-1.31
EBIT Margin	31.00%	20.58%	20.80%	3.78%	-6.34%
Effective Tax Rate	7.83%	8.53%	6.97%	28.72%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.